





Item 8.01. Other Events.

On October 26, 2017, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results from the Phase 2 multicenter trial of TG-1101 (ublituximab) in relapsing forms of Multiple Sclerosis (RMS) presented during the 7th JointECTRIMS – ACTRIMS meeting in Paris, France. On October 27, 2017, the Company announced additional results from the Phase 2 multicenter trial of TG-1101 in RMS presented during the 7th JointECTRIMS – ACTRIMS meeting. Copies of the press releases are being filed as Exhibits 99.1 and 99.2 and incorporated in this Item by reference.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press Release, dated October 26, 2017.

99.2 Press Release, dated October 27, 2017.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.  
(Registrant)

Date: October 27, 2017

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer